Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
Company to Host Conference Call and Webcast on August 7, 2024
公司將於2024年8月7日舉行電話會議和網絡直播
LOS ANGELES, July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates.
美國東部時間2024年8月7日上午8:30（太平洋時間上午5:30），專注於發展和商業化mTOR通路突變癌症治療方法的商業化精準腫瘤學公司Aadi Bioscience，Inc.（NASDAQ：AADI）今天宣佈，將於2024年8月7日星期三舉行電話會議和現場網絡直播，報告2024年第二季度財務業績並提供最新的企業更新。
Conference Call Information
Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.
電話會議信息
參與者可以在aadibio.com網站的“投資者新聞”頁面上訪問此次會議的網絡直播。如需通過電話參加，請在此處提前註冊: 電話會議註冊(vevent.com)。註冊後，所有電話參與者將收到一封確認電子郵件，其中詳細說明如何加入電話會議，包括撥入號碼以及可用於訪問會議的唯一密碼和註冊者ID。會議呼叫和網絡直播的重播將在網站上存檔至少30天。
About Aadi Bioscience, Inc.
Aadi is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. To unlock the full potential of mTOR inhibition, Aadi uniquely combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus. Aadi received FDA approval and commercializes FYARRO for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
關於Aadi Bioscience, Inc.
Aadi是一家商業化精準腫瘤學公司，專注於發展和商業化mTOR通路突變癌症的治療方法，mTOR是細胞生長和癌症進展的關鍵調節因子。爲了充分發揮mTOR的抑制作用，Aadi獨特地將納米粒子蛋白結合（nab）技術與強效的mTOR抑制劑西羅莫司相結合。Aadi已經獲得FDA批准並商業化 FYARRO，該藥用於治療局部晚期無法切除或轉移性惡性血管外上皮細胞瘤（PEComa）的成年患者。
Aadi is exploring nab-sirolimus in PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. Aadi is also exploring nab-sirolimus in two single-indication Phase 2 trials for difficult-to-treat mTOR-driven cancers: neuroendocrine tumors (NETs) of the lung, gastrointestinal tract and pancreas, and advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole. More information on Aadi's development pipeline is available on the Aadi website at and connect with us on Twitter and LinkedIn.
Aadi正在探索在PRECISION1中利用nab-西羅莫司治療惡性實體瘤，這是一項II期腫瘤獨立的登記試驗，針對運載酰胺結合納米粒子的微粒（nab）技術，其發揮的威力是最先進的mTOR抑制劑西羅莫司不能相提並論的。Aadi還在兩項針對難以治療的mTOR驅動癌症的II期單病種試驗中探索nab-西羅莫司: 肺，胃腸道和胰腺的神經內分泌腫瘤（NET）和晚期或復發的內膜型子宮內膜癌（EEC）與來曲唑聯合治療治療。有關Aadi的開發管道的更多信息，請訪問Aadi網站，並在Twitter和LinkedIn上與我們聯繫。
Contact:
[email protected]
聯繫方式：
[email protected]
SOURCE Aadi Bioscience
資料來源：Aadi Bioscience